RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion-Reference-Cited by-同舟云学术

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Published:2023-05 Issue:5 Volume:18 Page:576-586
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Aldea Mihaela^ORCID,Marinello Arianna,Duruisseaux Michael,Zrafi Wael,Conci Nicole,Massa Giacomo,Metro Giulio,Monnet Isabelle,Gomez Iranzo Patricia,Tabbo Fabrizio,Bria Emilio,Guisier Florian,Vasseur Damien,Lindsay Colin R.,Ponce-Aix Santiago,Cousin Sophie,Citarella Fabrizio,Fallet Vincent,Minatta Jose Nicolas,Eisert Anna,de Saint Basile Hortense,Audigier-Valette Clarisse,Mezquita Laura,Calles Antonio,Mountzios Giannis,Tagliamento Marco,Remon Masip Jordi,Raimbourg Judith,Terrisse Safae,Russo Alessandro,Cortinovis Diego,Rochigneux Philippe,Pinato David James,Cortellini Alessio,Leonce Camille,Gazzah Anas,Ghigna Maria-Rosa,Ferrara Roberto,Dall’Olio Filippo Gustavo,Passiglia Francesco,Ludovini Vienna,Barlesi Fabrice,Felip Enriqueta,Planchard David,Besse Benjamin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers;Adashek;Mol Cancer Ther,2021

2. Clinical and translational implications of RET rearrangements in non-small cell lung cancer;Ferrara;J Thorac Oncol,2018

3. RET fusion: joining the ranks of targetable molecular drivers in NSCLC;Osta;JTO Clin Res Rep,2020

4. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial;Drilon;Lancet Oncol,2016

5. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial;Yoh;Lancet Respir Med,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data;BMC Cancer;2024-02-05

2. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib;Critical Reviews in Oncology/Hematology;2024-02

3. Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report;Frontiers in Immunology;2024-01-03

4. Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting;JCO Precision Oncology;2024-01

5. Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer;Heliyon;2024-01